ProPhase Labs EBITDA 2010-2025 | PRPH

ProPhase Labs ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

ProPhase Labs EBITDA 2010-2025 | PRPH

ProPhase Labs ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.3B
Zoetis (ZTS)$67.6B
Takeda Pharmaceutical (TAK)$47B
Daiichi Sankyo, - (DSNKY)$46.1B
BeOne Medicines - (ONC)$33.7B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$20B
Merck (MKKGY)$16.8B
Shionogi (SGIOY)$15.5B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.6B
Madrigal Pharmaceuticals (MDGL)$8.3B
Corcept Therapeutics (CORT)$7.7B
Grifols, S.A (GRFS)$7.3B
Ionis Pharmaceuticals (IONS)$6.9B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
NewAmsterdam Pharma (NAMS)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B